JPWO2022032104A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022032104A5 JPWO2022032104A5 JP2023507428A JP2023507428A JPWO2022032104A5 JP WO2022032104 A5 JPWO2022032104 A5 JP WO2022032104A5 JP 2023507428 A JP2023507428 A JP 2023507428A JP 2023507428 A JP2023507428 A JP 2023507428A JP WO2022032104 A5 JPWO2022032104 A5 JP WO2022032104A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- aav particles
- pharmaceutical composition
- poloxamer
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063128P | 2020-08-07 | 2020-08-07 | |
| US202063063108P | 2020-08-07 | 2020-08-07 | |
| US63/063,128 | 2020-08-07 | ||
| US63/063,108 | 2020-08-07 | ||
| PCT/US2021/044955 WO2022032104A1 (en) | 2020-08-07 | 2021-08-06 | Formulations for highly purified viral particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536883A JP2023536883A (ja) | 2023-08-30 |
| JPWO2022032104A5 true JPWO2022032104A5 (https=) | 2024-08-14 |
| JP2023536883A5 JP2023536883A5 (https=) | 2024-08-14 |
Family
ID=80114720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507428A Pending JP2023536883A (ja) | 2020-08-07 | 2021-08-06 | 高度に精製されたウイルス粒子のための製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220040305A1 (https=) |
| EP (1) | EP4192437A4 (https=) |
| JP (1) | JP2023536883A (https=) |
| KR (1) | KR20230049670A (https=) |
| CN (1) | CN116323925A (https=) |
| AU (1) | AU2021320395A1 (https=) |
| CA (1) | CA3190596A1 (https=) |
| IL (1) | IL300323A (https=) |
| MX (1) | MX2023001411A (https=) |
| WO (1) | WO2022032104A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230212528A1 (en) * | 2020-06-02 | 2023-07-06 | Janssen Biotech, Inc. | Materials and methods for viral purification |
| WO2023028510A1 (en) * | 2021-08-24 | 2023-03-02 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| CN120603600A (zh) * | 2023-01-19 | 2025-09-05 | 优尼科生物制药有限公司 | 基因递送媒介物的药物配制品 |
| WO2024252024A1 (en) * | 2023-06-09 | 2024-12-12 | Sartorius Bia Separations D.O.O. | A method of enhanced separation of full adeno-associated virus (aav) capsids |
| CN121816201A (zh) * | 2023-09-01 | 2026-04-07 | 康霖生物科技（杭州）有限公司 | 一种液体制剂及其用途 |
| WO2025114524A1 (en) * | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| CN118957152B (zh) * | 2024-08-30 | 2025-11-25 | 浙江恒驭生物科技有限公司 | 一种腺相关病毒载体基因组滴度检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2420247A1 (en) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| EP1751275B1 (en) * | 2004-06-01 | 2017-08-16 | Avigen, Inc. | Compositions and methods to prevent aav vector aggregation |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| EA201890543A1 (ru) * | 2015-09-17 | 2018-08-31 | Рисёрч Инститьют Эт Нэйшнвайд Чилдрен'С Хоспитэл | Способы и материалы для генной терапии galgt2 |
| WO2019241535A2 (en) * | 2018-06-14 | 2019-12-19 | Regenxbio Inc. | Anion exchange chromatography for recombinant aav production |
| AU2019310459A1 (en) * | 2018-07-24 | 2021-02-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| US20220143115A1 (en) * | 2019-04-19 | 2022-05-12 | Regenxbio Inc. | Adeno-Associated Virus Vector Formulations and Methods |
-
2021
- 2021-08-06 AU AU2021320395A patent/AU2021320395A1/en not_active Abandoned
- 2021-08-06 KR KR1020237007796A patent/KR20230049670A/ko not_active Withdrawn
- 2021-08-06 CA CA3190596A patent/CA3190596A1/en active Pending
- 2021-08-06 EP EP21853878.3A patent/EP4192437A4/en active Pending
- 2021-08-06 JP JP2023507428A patent/JP2023536883A/ja active Pending
- 2021-08-06 US US17/396,090 patent/US20220040305A1/en not_active Abandoned
- 2021-08-06 CN CN202180067655.9A patent/CN116323925A/zh active Pending
- 2021-08-06 IL IL300323A patent/IL300323A/en unknown
- 2021-08-06 MX MX2023001411A patent/MX2023001411A/es unknown
- 2021-08-06 WO PCT/US2021/044955 patent/WO2022032104A1/en not_active Ceased
-
2025
- 2025-11-04 US US19/379,616 patent/US20260061059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351832B2 (en) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography | |
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| JP7531654B2 (ja) | アデノ随伴ウイルス精製方法 | |
| JP2021087431A5 (https=) | ||
| JP7539420B2 (ja) | アデノ随伴ウイルスの精製方法 | |
| JP5268890B2 (ja) | Ａａｖの規模適応性の製造方法 | |
| Burova et al. | Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications | |
| CN102803478B (zh) | 用于纯化重组aav载体的改进方法 | |
| JP2021526829A5 (https=) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JPWO2022032104A5 (https=) | ||
| WO2022191168A1 (ja) | 組換えａａｖ９ビリオンの製造方法 | |
| JPWO2020186207A5 (https=) | ||
| Youjin et al. | The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy | |
| JPWO2020237130A5 (https=) | ||
| JPWO2021221995A5 (https=) | ||
| JPWO2022155665A5 (https=) | ||
| HK1227436A1 (en) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography | |
| HK1227435A (en) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step | |
| HK1227435A1 (en) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |